Skip to main content

Cardio/Pulmonary

JAK Inhibitor Misses Endpoint in Safety Study. Now What?

MedPage Today
Jan 27, 2021

Pfizer announced results Wednesday from its FDA-mandated postmarketing safety study of tofacitinib (Xeljanz), and they don't bode well for the drug and possibly others in its class.



Compared with patients taking tumor necrosis factor (TNF) inhibitors, those assigned to tofacitinib (5

Read Article

Protective Effects of Colchicine in Non-Hospitalized COVID-19

Jan 25, 2021

A press release from Montreal Heart Institute announced that the COLCORONA clinical trial provided evidence of the protective effect of colchicine; demonstrating a 21% reduced risk of death or hospitalizations in patients with COVID-19 compared to placebo. COLCORONA trial was a contact-less,

Read Article

RheumNow Podcast – Don’t Hold the Benlysta, Take the Vaccine (1.22.2021)

Jan 22, 2021

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com, with more than a dozen items to discuss on this week's podcast.

Read Article

NEJM: Early Combo Monoclonal Antibody Therapy in COVID-19

Jan 21, 2021

NEJM has published the interim analysis of the REGN-COV2 trial, wherein an antibody cocktail reduced viral loads with less clinical consequences. 



Recent data suggest that high viral loads are associated with greater risk for COVID-19 complications and death. A combination of two

Read Article
Ehlers-Danlos Syndrome pts have higher association with GI conditions (IBS, etc OR =3.57), POTS & Autonomic dysfunction (OR=4.4), food allergy (OR= 3.9), CV complications (OR 6.1; MV dx, aortic aneurysm), longer hospitalizations (OR= 1.76) https://t.co/noobvrx0cQ

Dr. John Cush RheumNow ( View Tweet)

Jan 21, 2021

Low Risk of TB with Secukinumab

Jan 20, 2021

JAMA Dermatology has reported on a longitudinal cohort study of 12,319 secukinumab (SEC) treated patients (psoriasis, psoriatic arthritis, or ankylosing spondylitis); no new cases of active tuberculosis (TB) and very few cases of latent tuberculosis infection (LTBI) were found. 

Read Article

Mortality Risk in Rheumatoid Lung Patients

Jan 20, 2021

A Medicare claims analysis of rheumatoid arthritis (RA) patients showed that RA-associated interstitial lung disease (RA-ILD) was seen in nearly 5% of patients and was found to increase mortality risks, including respiratory and cancer mortality not explained by other factors.



Sparks

Read Article
Dr Stanley Cohen has written a nice review of VTE with JAK inhibitors, points out that little/no risk during developmental trials, is not the same as a low risk seen with long term use in real world patients (older, higher BMI, more activity) https://t.co/0utVMqHdf9

Dr. John Cush RheumNow ( View Tweet)

Jan 20, 2021
Swedish Rheumatology Quality Register study of 46316 RA pts (322601 visits) shows RA has a higher risk of venous thromboembolism (RR 1.88;95% CI 1.65, 2.15) & this increased with disease activity (RR=2.03;1.73 to 2.38) (compared to remission). https://t.co/R59tLy8WGx

Dr. John Cush RheumNow ( View Tweet)

Jan 20, 2021

2020 Rheumatology Year in Review

Jan 14, 2021

2020 was historic, memorable and game-changing. Under the cloud of COVID-19, there were many significant and memorable advances and setbacks for the rheumatology world. In our accounting of most read articles for 2020, (not surprisingly) 17/20 were COVID-related. Below, are our top news items

Read Article
Corticosteroid Use Hikes CV Risks in Rheumatic Patients--It is long known that high-dose steroids may increase the risk of cardiovascular disease (CVD), heart disease, stroke, or other vascular outcomes, but it is unknown what the risk is at lower doses. https://t.co/gkTLP3ceVD https://t.co/HMpvpham1q
Dr. John Cush RheumNow ( View Tweet)
Jan 12, 2021

Corticosteroid Use Hikes CV Risks in Rheumatic Patients

Jan 11, 2021

UK Clinical Practice Research Datalink population study shows that patients with immune-mediated inflammatory diseases, such as RA, PMR, GCA and IBD, have an augmented risk of CV outcomes with glucocorticoid use; even lower doses had a near doubling of their underlying CVD risk.

Read Article

RheumNow Podcast – Lights, Camera, Zoom (1.8.2021)

Jan 08, 2021

Dr. Jack Cush reviews the news, journal articles and favorite blogs from this past week on RheumNow.com.

Read Article
Rhapsody Study: IL-1 Inhibition in Recurrent Pericarditis RHAPSODY was a phase 3 multicenter, double-blind, event-driven, randomized-withdrawal trial of rilonacept in 86 patients with recurrent pericarditis Read more: https://t.co/syibq4X7Ps https://t.co/gnxlpOGiHA
Dr. John Cush RheumNow ( View Tweet)
Jan 08, 2021

Adherence to Hydroxychloroquine Lowers Lupus Mortality

Jan 07, 2021

A lupus cohort study from British Columbia, Canada has shown that medication adherence with hydroxychloroquine (HCQ) is associated with a 71% to 83% lower mortality. 

Read Article

Rhapsody Study: IL-1 Inhibition in Recurrent Pericarditis

Jan 06, 2021

Recurrent pericarditis is a rare, probable autoinflammatory disorder mediated by interleukin-1 (IL-1); and is often refractory to glucocorticoids and colchicine. A novel trial of IV rilonacept, an IL-1 α and IL-1β cytokine trap, resulted in rapid resolution of recurrent pericarditis and to a

Read Article
ENTRACTE trial studied the risk of major adverse CV events (MACE) in 3080 RA pts Rx with tocilizumab (TCZ) vs etanercept (ETN), and found no increased risk of MACE in TCZ patients compared to ETN (HR 1.05 (95% confidence interval 0.77–1.43). https://t.co/KpOEeVAAxx

Dr. John Cush RheumNow ( View Tweet)

Jan 02, 2021
#BestACR20Tweets RT @ATSCPAssembly : Dr. Dinesh Khanna ( @sclerodermaUM): In post-hoc analysis of focuSSed trial of tocilizumab vs. placebo, disease duration, male gender, elevated acute phase reactants, and anti-SCL-70 Ab have a larger beneficial effect on FVC in early SSc-ILD.

Dr. John Cush RheumNow ( View Tweet)

Dec 26, 2020

COVID-19 as a Leading Cause of Death in the USA

Dec 17, 2020

The exponential rise in deaths from the coronavirus (COVID-19) in the last several months is put into perspective by JAMA Viewpoint article noting that current US death rates of > 3000 per day from COVID-19 is greater than that seen in one day on September 11, 2001 (9/11 attacks, claimed 2988

Read Article
Lung Cancer Survival With Autoimmune Disease--a recent analysis suggests that patients with autoimmune disease do not have worse survival, even though they may have received less than the standard-of-care treatments. Learn more below. https://t.co/ItVhityI1B https://t.co/tyTKAtGY2O
Dr. John Cush RheumNow ( View Tweet)
Dec 17, 2020
Phase III RHAPSODY trial: open label rilonacept in 86 pts with active recurrent pericarditis (& elevated CRP). Rapid resolution was noted and during the drug withdrawal phase there were significantly fewer recurrences on rilonacept compared with placebo. https://t.co/oEGbsdKe8f

Dr. John Cush RheumNow ( View Tweet)

Dec 16, 2020
#UTSW Rheum Grand Rounds on Sarcoidosis w/ Dr. HSIA - Joints are involved in 15% of pts. Lung sking and ocular involvement predominate https://t.co/G4iWm4pLmO
Dr. John Cush RheumNow ( View Tweet)
Dec 10, 2020
#BestACR20Tweets RT @drdavidliew :The 'triple M' irAEs (myositis/myocarditis/MG): one of the rheumatic irAEs where autoAb are freq pos Nice systematic review: any autoAb+ 61% tested MG+ 59% tested MSA+ in 27% tested (18/67, 11 had myositis alone) https://t.co/aQHapPbjw9
Dr. John Cush RheumNow ( View Tweet)
Dec 07, 2020
#BestACR20Tweets RT @MeralElRamahiMD : A large observat study showed no difference in risk of major CV events in RA pts that were newly started on either MTX or HCQ. A greater stroke risk but lower risk of MI; hospitalized HF was seen in MTX initiators. #Abst1993 #ACR20

Dr. John Cush RheumNow ( View Tweet)

Dec 06, 2020
The Lungs: The Alpha and Omega of RA with Dr. Jonathan Kay #ACR20 https://t.co/zhCRaeKOfu https://t.co/zVwgzu9ULs
Dr. John Cush RheumNow ( View Tweet)
Dec 03, 2020
×